Lactoferrin

Evidence Fact Sheet

bovine bLF · recombinant rhLF

Lactoferrin is an iron-binding glycoprotein (bovine bLF; recombinant rhLF) studied for immune, iron-status, gut and skin markers via iron sequestration, LPS neutralization and NF-kB modulation. Human meta-analyses cover H. pylori eradication, anemia and respiratory infections; a large preterm-sepsis RCT was null. bLF is GRAS (US) and an authorized EU Novel Food.

Also known as: bLF (bovine lactoferrin) · rhLF (recombinant human lactoferrin) · Lactoferricin (derived peptide)

Overview

Lactoferrin is an iron-binding glycoprotein naturally present in milk, saliva and other secretions; supplements use bovine lactoferrin (bLF) or, increasingly, precision-fermented recombinant human lactoferrin (rhLF). Proposed mechanisms include broad-spectrum iron sequestration (it binds two Fe3+ ions per molecule with very high affinity), direct LPS/Lipid-A binding and endotoxin neutralization, NF-kB pathway inhibition, immune-cell modulation, and receptor-mediated enteral iron transport plus gut-barrier and microbiota support. Human studies typically use 100-600 mg/day bLF (around 100-250 mg/day in iron-status trials), with acid/heat-sensitive activity often preserved by enteric coating or microencapsulation. Regulatory status: bLF is GRAS in the US (multiple GRAS notices) and an authorized Novel Food in the EU with no approved health claim, and is permitted as a supplement constituent in Brazil (ANVISA); recombinant rhLF remains regulatorily lagging (not an authorized EU Novel Food) and its human evidence is sparse, so bLF clinical data should not be attributed to rhLF products. Educational evidence summary only, not clinical or self-medication guidance.

Mechanism of Action

Iron sequestration broad-spectrum bacteriostasis (binds 2 Fe3+ per molecule, ~300x transferrin affinity, depriving pathogens of iron) · Direct LPS / Lipid A binding and endotoxin neutralization · HSPG binding blocking initial viral adhesion (in vitro) · NF-kB (p65/p50) pathway inhibition, downregulating TNF-a / IL-6 / IL-8 · Immune-cell modulation (NK-cell activity, T-cell proliferation, phagocyte activation) · Gut-microbiota modulation (selective Bifidobacterium growth promotion) and tight-junction (ZO-1, occludin) barrier support · Receptor-mediated (LRP1 / TfR) enteral iron transcytosis supporting iron uptake · Osteoblast differentiation promotion / osteoclast inhibition (preliminary)

Body systems: Immune System · Digestive & Gut · Blood & Hematopoiesis · Skin & Connective Tissue · Oral & Dental · Musculoskeletal · Vision · Mitochondrial & Cellular Energy · Cellular Renewal

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Lactoferrin is not characterized as a treatment for any disease.

H. pylori eradication (adjuvant to standard therapy)

Meta-analysis supported

OR 2.26eradication · 95% CI 1.70-3.00
9 RCTs · n=1343pooled trials
86.57% vs 74.44%eradication rate LF vs control

In a meta-analysis of nine randomized trials, adding lactoferrin to standard H. pylori eradication therapy was associated with higher pooled eradication rates and a lower occurrence of total side-effects than control, with a particularly large reduction in nausea.

Reported effect: Pooled eradication 86.57% (95% CI 83.99-89.15%) vs 74.44% (95% CI 71.14-77.74%); OR 2.26 (95% CI 1.70-3.00); nausea summary OR 0.15 (95% CI 0.04-0.54)

“We identified nine randomized trials (n = 1343). Pooled H. pylori eradication rates were 86.57% (95% confidence interval (CI) = 83.99-89.15%) and 74.44% (95% CI = 71.14-77.74%) ... the odds ratio (OR) was 2.26 (95% CI = 1.70-3.00) ... summary OR was 0.15 (95% CI = 0.04-0.54) for nausea”

Source: PMID 19298339 · Zou 2009 · Helicobacter

Iron status / low hemoglobin (vs iron supplementation)

Meta-analysis supported

A systematic review and meta-analysis comparing oral bovine lactoferrin with iron supplementation in people with low hemoglobin found a statistically significant pooled increase in hemoglobin favoring lactoferrin, though heterogeneity was very high (I2 = 95.8%). Authors framed lactoferrin as a potentially safer, high-compliance alternative for those experiencing side effects from iron.

Effect size: not quantified on this page — see the linked study below for the reported figures.

Source: PMID 38291525 · Christofi 2024 · BMC Nutr

Respiratory tract infections (prevention)

Meta-analysis supported

OR 0.57RTI risk · 95% CI 0.44-0.74
6 RCTs · n=1194meta-analysis pool

A meta-analysis of randomized controlled trials reported that lactoferrin supplementation was associated with a lower risk of respiratory tract infections versus control, with a pooled odds ratio below 1 across roughly 1,200 participants.

Reported effect: Pooled OR 0.57 (95% CI 0.44 to 0.74) for respiratory tract infections; 6 RCTs included in the meta-analysis, n=1,194

“six were included in the meta-analysis ... n = 1,194 ... pooled odds ratio = 0.57; 95% confidence interval 0.44 to 0.74”

Source: PMID 34620326 · Ali 2021 · Clin Nutr ESPEN

Acne vulgaris (oral adjunct, skin markers)

RCT supported

-38.6%inflammatory lesions vs placebo
-23.1%total lesion count
200 mg/d · 12 wk · n=36double-blind design

In a 12-week double-blind, placebo-controlled trial, fermented milk providing 200 mg/day of lactoferrin was associated with significant decreases in inflammatory lesion count, total lesion count, acne grade and skin-surface sebum versus placebo in adults with acne vulgaris. The trial was small (18 per arm) and used a fermented-milk vehicle.

Reported effect: vs placebo at 12 wk: inflammatory lesions -38.6%, total lesions -23.1%, acne grade -20.3%, sebum content -31.1% (n=18 per group)

“the lactoferrin group showed significant decreases in inflammatory lesion count by 38.6%, total lesion count by 23.1%, and acne grade by 20.3% compared with the placebo group at 12 wk ... sebum content in the lactoferrin group was decreased by 31.1% compared with the placebo group”

Source: PMID 20692602 · Kim 2010 · Nutrition

Late-onset sepsis in very preterm infants (clinical setting) — honest negative

Null / no benefit RCT supported

RR 0.95late-onset infection · 95% CI 0.86-1.04
p=0.233not significant
29% vs 31%infection rate LF vs control

The large ELFIN randomized placebo-controlled trial found that enteral bovine lactoferrin did NOT reduce late-onset infection in very preterm infants: 29% in the lactoferrin group vs 31% in control, with an adjusted risk ratio crossing 1 and a non-significant p-value. This well-powered null result tempered earlier smaller positive trials and applies to a hospital/clinical setting only.

Reported effect: 316/1093 (29%) late-onset infection with lactoferrin vs 334/1089 (31%) control; adjusted RR 0.95 (95% CI 0.86-1.04; p=0.233)

“316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0.95 (95% CI 0.86-1.04; p=0.233).”

Source: PMID 30635141 · ELFIN trial investigators group 2019 · Lancet

Dosage (research context · not a recommendation)

100-600 mg/day bLF in human studies (immune/microbiota); 100-250 mg/day for iron-status outcomes (pregnancy/infant trials); 200 mg/day x 8-12 weeks in the acne RCT; EFSA assessed no safety concern up to 1000 mg/day adult supplement. Educational reference only — acid/heat-sensitive protein, enteric coating / microencapsulation used to preserve activity.

Regulatory Status · 4 Markets

US · FDA: GRAS — bovine lactoferrin (Morinaga GRN 000077; multiple GRAS notices incl. GRN 130/423/464/465/669). Lawful as a dietary-supplement ingredient under DSHEA; structure/function claims only (FDA disclaimer required). rhLF: some firms hold FDA No Objection Letter / self-affirmed GRAS (Helaina Effera 2023; TurtleTree LF+ 2024; precision-fermented rhLF GRN 1284 no questions). 'GRAS' is not 'FDA approval'.
EU · EFSA: bLF authorized as a Novel Food — Commission Implementing Decisions 2012/725/EU (Morinaga) + 2012/727/EU (FrieslandCampina), Reg (EU) 2017/2470 Union List. EFSA 2012 safety opinion passed (≤1000 mg/day adult). Max concentrations set by product category (infant formula 100 mg/100g; sports drinks 300 mg/100g; etc.). NO authorized health claim under Reg 432/2012. Precision-fermented rhLF: NOT authorized as a Novel Food.
BR · ANVISA: bLF authorized — IN 28/2018 authorized constituent (bovine lactoferrin); permitted in infant formula (RDC 43/2011) and dietary supplements (RDC 243/2018). Colostrum products permitted (≥19 yrs, ≤4 g/day). No disease-reduction claims. rhLF: assessed as a novel constituent, no approval to date.

Safety

EFSA found no safety concern for bLF up to 1000 mg/day (adult) and 100 mg/100 kcal (infant formula); long-term RCTs at 200-600 mg/day reported no serious adverse events; occasional mild bloating/loose stools. IMPORTANT: bovine lactoferrin may contain residual milk-protein allergens (notably beta-lactoglobulin) — caution in cow's-milk-protein-allergic individuals. rhLF (precision-fermented) theoretically avoids bovine allergens. rhLF/recombinant variants are regulatorily lagging (no EU Novel Food / no CN approval) and their human evidence is sparse; bLF clinical data must not be attributed to rhLF products. Pregnancy/lactation/infant use is documented in trials but a clinical/educational context only — not self-medication guidance.

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

PMID 19298339 · Zou 2009 · Helicobacter — H. pylori eradication (adjuvant to standard therapy)
PMID 38291525 · Christofi 2024 · BMC Nutr — Iron status / low hemoglobin (vs iron supplementation)
PMID 34620326 · Ali 2021 · Clin Nutr ESPEN — Respiratory tract infections (prevention)
PMID 20692602 · Kim 2010 · Nutrition — Acne vulgaris (oral adjunct, skin markers)
PMID 30635141 · ELFIN trial investigators group 2019 · Lancet — Late-onset sepsis in very preterm infants (clinical setting) — honest negative

Frequently Asked Questions

1. What is lactoferrin and where does it come from?

Lactoferrin is an iron-binding glycoprotein found naturally in milk, saliva, tears and other secretions. Supplements use either bovine lactoferrin (bLF) extracted from cow's milk or precision-fermented recombinant human lactoferrin (rhLF). Proposed mechanisms include iron sequestration (binding two Fe3+ ions per molecule with high affinity), LPS/endotoxin neutralization, NF-kB pathway inhibition, and gut-barrier and microbiota support.

2. Is there any strong negative evidence?

Yes. The large ELFIN randomized trial in very preterm infants found enteral lactoferrin did not reduce late-onset infection (29% vs 31%; adjusted RR 0.95, 95% CI 0.86-1.04, p=0.233). This well-powered null result is an important honest negative that tempered earlier smaller positive studies, and it applies only to a hospital/clinical setting.

3. Are bovine and recombinant lactoferrin interchangeable?

No. Nearly all of the clinical evidence above is from bovine lactoferrin (bLF), which is GRAS in the US and an authorized Novel Food in the EU. Recombinant human lactoferrin (rhLF) is regulatorily lagging (not an authorized EU Novel Food) and has sparse human data, so bLF trial results should not be attributed to rhLF products.

Last evidence review: 2026-06-27

← Evidence library